Clinical Trials Browser

NCT05554354 2026-03-03

Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

Phase 2 Terminated

1 enrolled

Breast

Anatomic Stage IV Breast Cancer AJCC v8

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT03289039 2026-01-22

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2 Terminated

21 enrolled 15 charts

Breast

Breast Neoplasms

NCT05082025 2026-01-09

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Phase 2 Terminated

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms, Endometrial Neoplasms

NCT06408168 2026-01-05

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Phase 2 Terminated

6 enrolled

Carcinoma, Lobular

NCT04024436 2025-11-13

A Study of TAS-120 in Patients With Metastatic Breast Cancer

Phase 2 Terminated

64 enrolled 21 charts

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04899349 2024-10-09

EPIK-B4

Phase 2 Terminated

2 enrolled 8 charts

Breast

Breast Neoplasms, Hyperglycemia, Hereditary Sensory and Autonomic Neuropathies

NCT05966584 2024-08-29

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast

Breast Neoplasms, Exanthema

NCT04862143 2024-06-20

TELEPIK

Phase 2 Terminated

2 enrolled 10 charts

Breast

Advanced Breast Cancer

NCT04738292 2024-05-03

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Phase 2 Terminated

11 enrolled 10 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT01953926 2024-03-12

SUMMIT

Phase 2 Terminated

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT05085002 2024-03-12

A Study of Lerociclib in Participants With Advanced Breast Cancer

Phase 2 Terminated

100 enrolled

Breast

Advanced Breast Cancer

NCT03322215 2024-03-08

PASIPHAE

Phase 2 Terminated

42 enrolled

Breast

Breast Cancer Metastatic

NCT05932667 2023-12-21

DEMETER

Phase 2 Terminated

1 enrolled

Breast

Breast Neoplasms

NCT04305236 2023-06-06

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer

Phase 2 Terminated

1 enrolled 5 charts

Breast

Breast Neoplasms

NCT03386162 2022-11-28

SAFIR-PI3K

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03584009 2022-06-28

Veronica

Phase 2 Terminated

103 enrolled 19 charts

Breast

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast

Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT02569801 2021-04-23

HydranGea

Phase 2 Terminated

71 enrolled 12 charts

Breast

Breast Neoplasms

NCT00570258 2021-03-30

Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy

Phase 2 Terminated

27 enrolled 7 charts

Breast

Breast Neoplasms

NCT00138125 2020-10-19

Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer

Phase 2 Terminated

2 enrolled 5 charts

Breast

Breast Neoplasms

NCT03241810 2020-09-02

SHERBOC

Phase 2 Terminated

22 enrolled 16 charts

Breast

Breast Neoplasms

NCT02374099 2018-12-14

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Phase 2 Terminated

97 enrolled 18 charts

Breast

Breast Neoplasms

NCT00722072 2018-02-26

Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy

Phase 2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT00932152 2017-10-19

Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer

Phase 2 Terminated

3 enrolled 6 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00752986 2016-12-05

ZACFAST

Phase 2 Terminated

39 enrolled 7 charts

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01528345 2016-07-11

Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Phase 2 Terminated

97 enrolled 10 charts

Breast

Breast Neoplasms

NCT00217464 2015-04-16

Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Phase 2 Terminated

17 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT00183963 2014-05-22

A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)

Phase 2 Terminated

4 enrolled 8 charts

Breast

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

15 enrolled

Breast

Breast Neoplasms

NCT01233947 2012-01-09

Study of AFP464 +/- Faslodex in ER + Breast Cancer

Phase 2 Terminated

7 enrolled

Breast

Breast Neoplasms

NCT00774878 2011-03-03

Study of AVE1642 (IGF-1R/CD221) in Combination With Fulvestrant (Faslodex®) in Postmenopausal Patients With Advanced Hormono-dependent Breast Cancer

Phase 2 Terminated

18 enrolled

Breast

Breast Neoplasms